HomeAI · summaries
Storia in 7 fonti
Merck beats AstraZeneca to first approval for first PCSK9 pill
Merck's Lipfendra beats AstraZeneca's laroprovstat to become the first oral PCSK9 pill, priced at $10.50/day with $370M in 2027 sales forecast.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
- ·
healio.com
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…
- ·
endpoints.news
Merck beats AstraZeneca to first approval for first PCSK9 pill
Merck's Lipfendra beats AstraZeneca's laroprovstat to become the first oral PCSK9 pill, priced at $10.50/day with $370M in 2027 sales forecast.
- ·
cnn.com
Merck’s cholesterol pill gets US FDA approval | CNN
Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s nod, bolstering the drugmaker’s efforts to…
- ·
nbcnews.com
FDA approves new kind of cholesterol pill
Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.
- ·
benzinga.com
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)
Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.
- ·
economictimes.indiatimes.com
Merck gets US FDA nod for first-in-its-class oral cholesterol drug
The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra…